How were Codiak BioSciences' earnings last quarter?

Codiak BioSciences, Inc. (NASDAQ:CDAK) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.12. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $2.87 million. Codiak BioSciences had a negative trailing twelve-month return on equity of 109.51% and a negative net margin of 51.13%.

When did Codiak BioSciences IPO?

Codiak BioSciences (CDAK) raised $82 million in an IPO on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow acted as the underwriters for the IPO.

NASDAQ:CDAK

Codiak BioSciences (CDAK) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free CDAK Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.0016
▼
$0.0016
50-Day Range: N/A
52-Week Range: $0.05
▼
$6.98

Volume: N/A
Average Volume: 1.37 million shs
Market Capitalization: $58,928.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Codiak BioSciences alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Codiak BioSciences Stock (NASDAQ:CDAK)

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

CDAK Stock News Headlines

January 13, 2024 | morningstar.com

Marvel Biosciences Corp MRVL

May 19, 2023 | finance.yahoo.com

Mariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial Officer

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 15, 2023 | reuters.com

CDAK.O

April 2, 2023 | benzinga.com

How Does Codiak BioSciences Inc (CDAK) Stock Rank on Wall Street Friday?

March 27, 2023 | finance.yahoo.com

Codiak BioSciences Files For Chapter 11 Bankruptcy

March 27, 2023 | marketwatch.com

Codiak BioSciences Shares Hit 52-Week Low After Bankruptcy Filing

March 27, 2023 | bizjournals.com

Struggling MD Anderson spinout files for bankruptcy protection

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 27, 2023 | benzinga.com

Codiak BioSciences shares are trading lower after the company voluntarily filed for protection under Chapter 11 bankruptcy.

March 27, 2023 | finanznachrichten.de

Codiak BioSciences, Inc.: Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

March 27, 2023 | reuters.com

COVID vaccine developer Codiak files for US bankruptcy protection

March 27, 2023 | msn.com

Codiak Bio Tumbles on Bankruptcy Filing

March 27, 2023 | markets.businessinsider.com

Codiak BioSciences Voluntarily Files For Bankruptcy Protection

March 27, 2023 | finance.yahoo.com

Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

March 22, 2023 | seekingalpha.com

CDAK Codiak BioSciences, Inc.

March 3, 2023 | msn.com

Laurion Capital Management Now Owns 9.60% of Codiak BioSciences (CDAK)

February 21, 2023 | bizjournals.com

Blood disorder startup Hemab Therapeutics raises $135M

November 28, 2022 | finance.yahoo.com

Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

November 10, 2022 | finance.yahoo.com

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

November 9, 2022 | finance.yahoo.com

Codiak BioSciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 4, 2022 | finance.yahoo.com

Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates

November 3, 2022 | technews.tmcnet.com

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

November 3, 2022 | finance.yahoo.com

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

October 19, 2022 | finance.yahoo.com

All You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong Buy

October 12, 2022 | finance.yahoo.com

Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses

October 6, 2022 | finance.yahoo.com

Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization

See More Headlines

Receive CDAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CDAK
CUSIP: N/A
CIK: 1659352
Web: www.codiakbio.com
Phone: 617-949-4100
Fax: N/A
Employees: 102
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,160,000.00
Net Margins: -51.13%
Pretax Margin: -51.13%
Return on Equity: -109.51%
Return on Assets: -34.44%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 4.24
Quick Ratio: 4.24

Sales & Book Value

Annual Sales: $33.57 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.39 per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 36,830,000
Free Float: 33,810,000
Market Cap: $58,928.00
Optionable: Not Optionable
Beta: 3.71

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Douglas Edward Williams Ph.D. (Age 64)
Pres, CEO & Director
Comp: $970.77k
Ms. Linda Cathavina Bain CPA (Age 52)
CFO & Treasurer
Comp: $602.54k
Dr. Sriram Sathyanarayanan Ph.D. (Age 50)
Chief Scientific Officer
Comp: $502.17k
Dr. Konstantin Konstantinov Ph.D. (Age 64)
Chief Technology Officer
Mr. Christopher J. M. Taylor
VP of Investor Relations & Corp. Communications
Ms. Yalonda Howze (Age 50)
Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
Ms. Nicole Barna (Age 48)
Sr. VP of HR
Dr. David J. Mauro M.D. (Age 57)
Ph.D., Chief Medical Officer
Dr. Benny Sorensen M.D. (Age 48)
Ph.D., Member of Scientific Advisory Board & Consultant

Key Competitors

View All Competitors

CDAK Stock Analysis - Frequently Asked Questions

How were Codiak BioSciences' earnings last quarter?: Codiak BioSciences, Inc. (NASDAQ:CDAK) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.12. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $2.87 million. Codiak BioSciences had a negative trailing twelve-month return on equity of 109.51% and a negative net margin of 51.13%.
When did Codiak BioSciences IPO?: Codiak BioSciences (CDAK) raised $82 million in an IPO on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow acted as the underwriters for the IPO.

This page (NASDAQ:CDAK) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Codiak BioSciences (CDAK) Stock Price, News & Analysis

About Codiak BioSciences Stock (NASDAQ:CDAK)

CDAK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CDAK Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info